You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

R/M HNSCC (Recurrent/metastatic Head and Neck Squamous Cell Carcinoma)

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) Trial in Pittsburgh (Pembrolizumab, Carboplatin,

Not yet recruiting
  • Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Sep 18, 2023

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Trial in Shanghai (Dalpiciclib+cetuximab)

Recruiting
  • Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
  • Shanghai, Shanghai, China
    the Ninth People's Hospital Affiliated to Shanghai Jiao Tong Uni
Feb 9, 2023

Head and Neck Squamous Cell Carcinoma Trial in Candiolo (inulin, Pembrolizumab, Nivolumab)

Recruiting
  • Head and Neck Squamous Cell Carcinoma
  • inulin
  • +2 more
  • Candiolo, Turin, Italy
    Fondazione del Piemonte per l'Oncologia-IRCCS Candiolo
Apr 7, 2023

Pembrolizumab in the First Line Therapy for R/M HNSCC in China

Recruiting
  • Head and Neck Squamous Cell Carcinoma
  • Beijing, China
    Cancer Institute/Hospital, Chinese Academy of Medical Sciences &
Feb 4, 2022

Head and Neck Squamous Cell Carcinoma Trial in Beijing (Pembrolizumab combined with Chemotherapy)

Recruiting
  • Head and Neck Squamous Cell Carcinoma
  • Pembrolizumab combined with Chemotherapy
  • Beijing, Beijing, China
    National Cancer Center/Cancer Hospitial,Chinese Academy of Medic
Feb 4, 2022

HNSCC Trial in United States (Tipifarnib, Alpelisib)

Recruiting
  • HNSCC
  • Duarte, California
  • +10 more
Jun 30, 2022

Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma Trial in Shanghai

Recruiting
  • Recurrent Head and Neck Squamous Cell Carcinoma
  • Metastatic Head and Neck Squamous Cell Carcinoma
  • Shanghai, China
    the Ninth People's Hospital Affiliated to Shanghai Jiao Tong Uni
Dec 5, 2021

Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma Trial (Ficlatuzumab,

Not yet recruiting
  • Metastatic Head-and-neck Squamous-cell Carcinoma
  • Recurrent Head and Neck Squamous Cell Carcinoma
  • Ficlatuzumab
  • +2 more
  • (no location specified)
Sep 26, 2023

Head and Neck Squamous Cell Carcinoma Trial (Zanzalintinib, Zanzalintinib-matched Placebo, Pembrolizumab)

Not yet recruiting
  • Head and Neck Squamous Cell Carcinoma
  • (no location specified)
Oct 9, 2023

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Trial (Nimotuzumab, Sintilimab, Chemotherapy drug)

Not yet recruiting
  • Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
  • (no location specified)
May 6, 2021

Squamous Cell Carcinoma of the Head and Neck (SCCHN), Recurrent Squamous Cell Carcinoma of the Head and Neck, Metastatic Head

Recruiting
  • Squamous Cell Carcinoma of the Head and Neck (SCCHN)
  • +4 more
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Jan 19, 2023

Recurrent Head Neck Cancer, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma Trial in Saint

Not yet recruiting
  • Recurrent Head and Neck Cancer
  • +5 more
  • Saint Louis, Missouri
    Washington University School of Medicine
Jul 30, 2023

Head Neck Cancer, Squamous Cell Carcinoma of the Head and Neck Trial in La Jolla (Ibrutinib 560mg PO daily (Imbruvica),

Active, not recruiting
  • Head and Neck Cancer
  • Squamous Cell Carcinoma of the Head and Neck
  • Ibrutinib 560mg PO daily (Imbruvica)
  • +2 more
  • La Jolla, California
    UCSD Moores Cancer Center
Jan 11, 2023

HNSCC Trial (Danvatirsen, Pembrolizumab)

Not yet recruiting
  • HNSCC
  • (no location specified)
Apr 3, 2023

Squamous Cell Carcinoma of Head and Neck Trial in Shanghai (Camrelizumab+cetuximab+chemo)

Not yet recruiting
  • Squamous Cell Carcinoma of Head and Neck
  • Shanghai, China
    Fudan University
Jan 4, 2023

HPV-Related Squamous Cell Carcinoma, HNSCC Trial in London (VB10.16, Pembrolizumab)

Not yet recruiting
  • HPV-Related Squamous Cell Carcinoma
  • HNSCC
  • London, United Kingdom
    East and North Hertfordshire NHS Trust Mount Vernon Hospital
Aug 24, 2023

Sinonasal Cancer, Squamous NSCLC, Lung Cancer Trial run by the National Cancer Institute (NCI) (pembrolizumab, valemetostat)

Not yet recruiting
  • Sinonasal Cancer
  • +5 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jun 5, 2023

Head and Neck Squamous Cell Carcinoma, Head Neck Cancer Trial (Tislelizumab, BGB-A425, LBL-007)

Not yet recruiting
  • Head and Neck Squamous Cell Carcinoma
  • Head and Neck Cancer
  • (no location specified)
Jun 9, 2023

Head and Neck Squamous Cell Carcinoma Trial (TTI-101, Pembrolizumab)

Not yet recruiting
  • Head and Neck Squamous Cell Carcinoma
  • (no location specified)
Dec 20, 2022

Head and Neck Squamous Cell Carcinoma Trial in Chongqing (Camrelizumab, Stereotactic body radiotherapy)

Recruiting
  • Head and Neck Squamous Cell Carcinoma
  • Chongqing, Chongqing, China
    Chongqing University Cancer Hospital
Mar 31, 2021

Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC) Trial in United States (pepinemab + pembrolizumab)

Recruiting
  • Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)
  • pepinemab + pembrolizumab
  • Springdale, Arkansas
  • +17 more
Dec 7, 2022

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Trial (Pembrolizumab, Cisplatin, Carboplatin)

Recruiting
  • Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
  • Kuala Lumpur, Malaysia
    University Malaya Medical Centre
Nov 1, 2022

Prognostic Immune Biomarkers in HNSCC

Completed
  • Head and Neck Cancer
  • Squamous Cell Carcinoma
  • Tumour immunoprofile evaluation
  • Ostrava, Moravian-Silesian Region, Czechia
    University Hospital Ostrava
Jul 3, 2023

Head Neck, Squamous Cell Carcinoma of Head and Neck Trial in Houston (Pembrolizumab, Magrolimab, cetuximab)

Not yet recruiting
  • Head Neck
  • Squamous Cell Carcinoma of Head and Neck
  • Houston, Texas
    M D Anderson Cancer Center
Sep 14, 2023

Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head-and-neck Squamous-cell Carcinoma, Locally Advanced Cutaneous

Active, not recruiting
  • Recurrent Head and Neck Squamous Cell Carcinoma
  • +3 more
  • 200 mg Pembrolizumab
  • +2 more
  • Miami, Florida
  • +6 more
Jan 9, 2023